|
Wendell Wierenga brings more than 30 years of biotechnology and pharmaceutical experience to Ambit. In addition to his current board position and management role at Ambit, Wierenga holds board of director's positions at XenoPort and Onyx Pharmaceuticals as well as a scientific advisory board position at Concert Pharmaceuticals. He previously served as Executive Vice President of R&D at Neurocrine Biosciences, where he managed a portfolio of six clinical programs including five INDs and two NDAs. Prior to Neurocrine Biosciences, he served as Chief Executive Officer of Syrrx, Inc. (now Takeda San Diego) and as Senior Vice President of Worldwide Pharmaceutical Sciences, Technologies and Development at Parke-Davis/Warner Lambert (now Pfizer), where he was responsible for worldwide drug development. Prior to joining Parke-Davis, Wierenga spent 16 years at Upjohn Pharmaceuticals, where he lead cancer and infectious diseases research and later drug discovery research. He led/participated in the research and development of more than 60 INDs, 10 NDAs and 10 marketed products, including Lipitor(r) and Neurontin(r). Wierenga earned his Ph.D. in chemistry from Stanford University and completed an American Cancer Society Postdoctoral Fellowship at Stanford. He earned his B.A. from Hope College in Holland, Michigan. | 